Aseela Fathima

Ms. Aseela Fathima


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2025 in Biology
Verified
Journal Article
Open access
PDF file
SASarah Aqel
Sarah Aqel
JAJamil Ahmad
Jamil Ahmad
ISIman Saleh
Iman Saleh
AFAseela Fathima
Aseela Fathima
ATAsmaa A. Al Thani
Asmaa A. Al Thani
Abdullah A. ShaitoAbdullah A. Shaito
Abdullah A. Shaito
Neurodegenerative disorders (NDs) cause progressive neuronal loss and are a significant public health concern, with NDs projected to become the second leading global cause of death within two decades. Huntington’s disease (HD) is a rare, progressive ND caused by an autosomal-dominant mutation in the huntingtin (HTT) gene, leading to severe neuronal loss in the brain and resulting in debilitating motor, cognitive, and psychiatric symptoms. Given the complex pathology of HD, biomarkers are essential for performing early diagnosis, monitoring disease progression, and evaluating treatment efficacy. However, the identification of consistent HD biomarkers is challenging due to the prolonged premanifest HD stage, HD’s heterogeneous presentation, and its multiple underlying biological pathways. This study involves a 10-year bibliometric analysis of HD biomarker research, revealing key research trends and gaps. The study also features a comprehensive literature review of emerging HD biomarkers, concluding the need for better stratification of HD patients and well-designed longitudinal studies to validate HD biomarkers. Promising candidate wet HD biomarkers— including neurofilament light chain protein (NfL), microRNAs, the mutant HTT protein, and specific metabolic and inflammatory markers— are discussed, with emphasis on their potential utility in the premanifest HD stage. Additionally, biomarkers reflecting brain structural deficits and motor or behavioral impairments, such as neurophysiological (e.g., motor tapping, speech, EEG, and event-related potentials) and imaging (e.g., MRI, PET, and diffusion tensor imaging) biomarkers, are evaluated. The findings underscore that the discovery and validation of reliable HD biomarkers urgently require improved patient stratification and well-designed longitudinal studies. Reliable biomarkers, particularly in the premanifest HD stage, are crucial for optimizing HD clinical management strategies, enabling personalized treatment approaches, and advancing clinical trials of HD-modifying therapies.

5 December 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
SASarah Aqel
Sarah Aqel
JAJamil Ahmad
Jamil Ahmad
ISIman Saleh
Iman Saleh
AFAseela Fathima
Aseela Fathima
ATAsmaa A. Al Thani
Asmaa A. Al Thani
Abdullah A. ShaitoAbdullah A. Shaito
Abdullah A. Shaito
Neurodegenerative disorders (NDs) lead to progressive neuronal loss in various brain regions and are a significant public health concern, with NDs expected to become the second-leading cause of death globally within the next two decades. Huntington's disease (HD) is a rare progressive ND that severely impacts patients and families due to its severe neuronal effects. HD is caused by an autosomal dominant mutation in the huntingtin (HTT) gene, which leads to progressive motor, cognitive, and psychiatric symptoms. Given the complex nature of HD, biomarkers are essential for early diagnosis, disease progression monitoring, and evaluation of treatment efficacy. However, the identification of consistent HD biomarkers is challenging due to HD's heterogeneous presentation and its multiple underlying biological pathways. To identify reliable HD biomarkers, integration of research efforts through longitudinal studies that track disease progression, new biomarker exploration to enhance diagnostic accuracy, and collaborative efforts to standardize protocols and ensure reproducibility are warranted. These efforts should also advance personalized treatment approaches and improve the overall management of HD. This study provides a comprehensive review and bibliometric analysis of HD biomarker research over the past decade, revealing key research trends and gaps. The findings could guide future investigations and contribute to improving personalized treatment approaches, clinical management, and informed decision-making in HD.